A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study week 12 in patients with visual impairment due to diabetic macular edema

Trial Profile

A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study week 12 in patients with visual impairment due to diabetic macular edema

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Ranibizumab (Primary) ; Aflibercept
  • Indications Diabetic macular oedema
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms TIDE DME
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Oct 2016 Status changed from suspended to withdrawn prior to enrolment.
    • 15 Oct 2015 Planned End Date changed from 1 May 2016 to 1 Oct 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top